What happened with MGTX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MeiraGTx Holdings plc develops treatments for conditions including severe dry mouth, Parkinson’s disease and eye diseases, and makes clinical-trial material at its own facilities in London and Shannon, Ireland. It remains a clinical-stage company with no approved products and has not generated product-sales revenue.
Most disclosed revenue comes from Lilly’s upfront payment for exclusive worldwide rights to selected eye-disease programs and related technology. Lilly pays to develop and commercialize those medicines; MeiraGTx can earn further payments when agreed milestones are reached and royalties if products sell. Johnson & Johnson Innovative Medicine separately bought the RPGR eye-disease program and pays MeiraGTx for manufacturing qualification services. That work is substantially complete, while a supply agreement provides for MeiraGTx to manufacture the product for commercial sale if approved.
Cash from these arrangements depends on partners advancing programs, securing approvals and reaching contractual milestones. Johnson & Johnson controls much of the work that determines future RPGR payments. A planned Hologen collaboration would fund neurological programs and part of the manufacturing business; Hologen has paid part of the upfront commitment, but closing and remaining funding are conditional. MeiraGTx and its partners cannot market the medicines before obtaining the required regulatory approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond approvals and partner milestone payments, MeiraGTx depends materially on Hologen’s collaboration funding and progress in their AAV-GAD Parkinson’s joint venture.
Johnson & Johnson controls development and commercialization of the RPGR gene therapy it bought from MeiraGTx, paying MeiraGTx to manufacture it and potentially for milestones. Watch bota-vec’s first commercial sales in the United States and European Union and manufacturing technology transfer: together these could trigger up to $285 million for MeiraGTx.
Eli Lilly pays MeiraGTx for rights to eye-disease gene therapies and delivery technology and bears their research, development and commercialization costs. Its $75 million upfront fee became MeiraGTx’s 2025 license revenue; development and regulatory progress could unlock further milestones, with royalties possible on sales.
Opus Genetics competes with MeiraGTx in gene therapies that use AAV to carry genes into cells for inherited retinal diseases, specifically identifying MeiraGTx’s RDH12 program as a rival. Its RDH12 development news is the closest comparison for that part of MeiraGTx’s eye-disease pipeline.
Voyager Therapeutics competes with MeiraGTx in central nervous system gene therapies, including Parkinson’s, and both receive payments from drug-company partners for gene-delivery technology. Watch Voyager’s intravenously delivered programs using its TRACER carriers alongside MeiraGTx’s AAV-GAD, which is infused locally into the brain.
4D Molecular Therapeutics and MeiraGTx both depend on retinal gene therapies succeeding clinically and attracting licensing partners: Otsuka pays 4D for Asia-Pacific rights to 4D-150, while Lilly licenses MeiraGTx’s eye programs and delivery technology. Watch 4D-150’s global Phase 3 results as a readout for retinal gene therapy, not for the same inherited diseases targeted by MeiraGTx’s Lilly programs.
REGENXBIO offers a comparison for MeiraGTx’s reliance on drug-company partners in retinal AAV therapies: it develops sura-vec with AbbVie, while MeiraGTx licenses eye programs to Lilly and manufactures Johnson & Johnson’s RPGR therapy. Watch sura-vec’s progress in wet AMD and diabetic retinopathy for evidence of clinical and regulatory acceptance of retinal AAV treatments.
Taysha Gene Therapies is a comparison for the safety and gene-output control needed by MeiraGTx’s central nervous system AAV programs and gene-regulation platform. Watch its Rett syndrome treatment TSHA-102, designed to deliver functional MECP2 while limiting excess production; MeiraGTx instead uses oral small molecules to control gene output in its riboswitch platform.
Passage Bio and MeiraGTx share the need to prove both their neurodegenerative-disease gene therapies and the reliability of manufacturing the viruses that deliver them. Passage Bio’s PBFT02 for frontotemporal dementia is a comparison for MeiraGTx’s AAV medicines, with validated manufacturing a requirement for both.
Sarepta Therapeutics’ ELEVIDYS liver-safety problems affect scrutiny of AAV medicines, including those MeiraGTx develops and manufactures, although MeiraGTx uses different delivery routes. Watch ELEVIDYS safety and labeling news: in November 2025 Sarepta announced a boxed warning for acute liver injury and failure and removed non-ambulatory patients from its U.S. indication.
Fed Interest Rate Decision
The Fed’s decision affects what MeiraGTx pays on its Perceptive notes, whose interest rate resets with one-month SOFR, and therefore how much cash remains for its clinical programs and manufacturing facilities.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest on MeiraGTx’s floating-rate Perceptive notes, leaving less cash for clinical development and manufacturing investment.
If it comes in below expectations
Lower rates can reduce interest on MeiraGTx’s floating-rate Perceptive notes, leaving more cash available for clinical development and manufacturing investment.
MeiraGTx Holdings plc earningsThis company
MeiraGTx Holdings plc’s report will show whether ongoing partner work can replace service revenue from a nearly completed Johnson & Johnson manufacturing project.
Separate partner-service revenue from license revenue: Johnson & Johnson-related manufacturing services fell sharply in 2025, while Lilly’s license fee was an upfront payment, not product sales or recurring revenue. Continued service revenue alongside new milestone or license income would show that collaborations are still bringing in cash; falling service revenue without replacement payments would show that revenue remains dependent on irregular deals, not sales of approved products.
